Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins.

Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Abstract Text:

    tom schalekampTom Schalekamp,j h klungelJ H Klungel,patrick c souvereinPatrick C Souverein,anthonius de boerAnthonius de Boer,tom schalekampTom Schalekamp,olaf h klungelOlaf H Klungel,patrick c souvereinPatrick C Souverein,anthonius de boerAnthonius de Boer,

    BACKGROUND: Treatment with vitamin K antagonists (coumarins) is associated with an increased risk of bleeding. Because use of selective serotonin reuptake inhibitors (SSRIs) is also associated with an increased risk of bleeding, we assessed the odds ratio (OR) of abnormal bleeding associated with SSRI use in users of the coumarins acenocoumarol or phenprocoumon and compared this with the OR of bleeding as a result of use of nonsteroidal anti-inflammatory drugs. METHODS: We used data from a Dutch linkage system including pharmacy and linked hospitalization records for approximately 2 million subjects to conduct a case-control study in a cohort of new users of coumarins. Cases were patients who were hospitalized having a primary diagnosis of abnormal major bleeding while taking a coumarin and were matched with up to 4 control subjects. Conditional logistic regression analysis was used to determine ORs and 95% confidence intervals (CIs) for the risk of hospitalization because of abnormal bleeding associated with concurrent use of SSRIs or nonsteroidal anti-inflammatory drugs. RESULTS: We identified 1848 case patients with abnormal bleeding. Users of SSRIs were at significantly increased risk of hospitalization because of nongastrointestinal tract bleeding (hereafter referred to as "nongastrointestinal bleeding") (adjusted OR, 1.7; 95% CI, 1.1-2.5) but not because of gastrointestinal tract bleeding (hereafter referred to as "gastrointestinal bleeding") (adjusted OR, 0.8; 95% CI, 0.4-1.5). Users of nonsteroidal anti-inflammatory drugs had a similar increased risk of nongastrointestinal bleeding (adjusted OR, 1.7; 95% CI, 1.3-2.2), whereas the risk of gastrointestinal bleeding was higher (adjusted OR, 4.6; 95% CI, 3.3-6.5). CONCLUSION: In users of coumarins, SSRI usage was associated with increased risk of hospitalization because of nongastrointestinal bleeding but not because of gastrointestinal bleeding.

    Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Publishing Authors By Initials

    t schalekampT Schalekamp,jh klungelJH Klungel,pc souvereinPC Souverein,a de boerA de Boer,t schalekampT Schalekamp,oh klungelOH Klungel,pc souvereinPC Souverein,a de boerA de Boer,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Archives of internal medicine

    VOLUME: 168

    Page Numbers: 180-5

    Journal Abbreviation: Arch. Intern. Med.

    ISSN: 0003-9926

    DAY: 28

    MONTH: Jan

    YEAR: 2008

    Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 372440

    Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins.

    AFFILIATION: PharmD, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB Utrecht, the Netherlands. t.schalekamp@pharm.uu.nl.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Arch Intern Med

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News